titelfolie mit langer Überschrift, zwei- oder mehrzeilig, tt norms … · biologics market in...

54
Simplifying Progress Investors Presentation H1 2020 Results

Upload: others

Post on 15-Aug-2020

7 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

Simplifying Progress

Investors PresentationH1 2020 Results

Page 2: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

This presentation contains statements concerning the future performance of the Sartorius Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements.

Throughout this presentation, differences may be apparent as a result of rounding during addition.

Disclaimer

2

Page 3: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

Agenda

3

Overview | Strategy

Bioprocess Solutions Division

Lab Products & Services Division

FY 2020 Guidance | H1 2020 Results

Page 4: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

Partner of biopharmaceutical research and industry

4 Overview | Strategy

We empower scientists and engineers to simplify and accelerate progress in life science and bioprocessing, enabling the

development of new and better therapies and more affordable medicine.

Page 5: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

Based on FY 2019 figures 1 For continued operations, in constant currencies 2 Excluding extraordinary items

5

~€1.8bn Sales revenue

~14%Sales CAGR1 2014-2019

27.1%EBITDA margin2

9,016Employees

60+Locations worldwide, headquartered in Göttingen, Germany

High exposure to attractive biopharma and life science industry

~35%

€412m

€1,827m

Sales with life science customers

Group sales revenue

20192000

~85%

Overview | Strategy

Sartorius at a glance

Page 6: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

6

Strategic focus of both divisions on the biopharma value chain

Overview | Strategy

Lab Products & Services Division

Quality | Testing | Validation

Upstream & downstream production

Molecule development

Cell line and process development

Bioprocess Solutions Division

Page 7: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

7

Attractive market environment with strong growth opportunities

Overview | Strategy

~8% CAGR for biopharmamarket 2019–2025

Favorabledemographics

9bn people by 2050; >2bn 60 yrs or older

Rise ofbiosimilars

~30% CAGR for biosimilar sales 2019–2022

Strong R&D pipeline; advances in gene and cell therapy

>40% share of biologics in pharma R&D pipeline

Page 8: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

€733m

19.7 20.1 20.5 21.023.6

25.0 25.1 25.927.1

17.5

19.5

21.5

23.5

25.5

27.5

29.5

31.5

33.5

35.5

37.5

39.5

300

500

700

900

1100

1300

1500

1700

1900

2011 2012 2013 2014 2015 2016 2017 2018 2019

+12.6%+16.0%

+18.2%+9.3%

+8.8%

~€1.8bn

~€650m

+13.6%

+13.2%

8

Sales CAGR ~+13%+14.8%

EBITDA-margin1 +7.4pp

Sales growth and CAGR 2011-19 for continued operations, in constant currencies 1 Excluding extraordinary items

Sales revenue EBITDA1 margin in % Intec Division; divested in 2|2015

Overview | Strategy

Sales revenue has more than doubled over the last 5 years

Page 9: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

9

CAGR for continued operations, in constant currencies

53%

25%

22%

2011

~€650m

40%

35%

25%

2019

~€1.8bn

22%

51%

27%

2019

~€240bnCAGR

~+16%

~+16%

~+11%

Asia | Pacific

Americas

EMEA

Global biopharma market2019

Sales by region 2011

Sales by region 2019

Overview | Strategy

Regional balance better reflecting end-markets

Page 10: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

8.8 7.7 9.1 10.1 11.7 14.9 15.2 12.3~10.0

2012 2013 2014 2015 2016 2017 2018 2019 2020

Expansion of R&D facilities and headquarter

Major projects

Regular expansion

Capitalized R&D

Maintenance ~3%

~2%

~3%

~X%

1

1 Incl. discontinued operation 2 Based on 2020 guidance

1

CAPEX ratioin %

CAPEX composition 2020

2

10

Expansion of fermenter production capacities

Overview | Strategy

Infrastructure prepared for further organic growth

Page 11: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

11

Acquisition criteria

Portfolio: Complementary products or technologiesMarket position: Either among the Top 3 or unique selling pointIntegration: Management capacity; cultural fitPrice: Fair valuation; reach Sartorius‘ profitability level in 2-3 years

Overview | Strategy

M&A strategy – adding innovation, enhancing focus

TAP Biosystems

BioOutsource

Cellca kSep Umetrics

Intellicyt ViroCytEssen

BioScience

AllPureTechnologies

2013 2014 2015 2016 2017 20202018 2019

Biological Industries

DivestmentIntec Division

Life Science assets from Danaher

Page 12: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

Developer and manufacturer of cell culture media

Specializes in media for advanced therapies (cell and gene therapies)

~130 employees; headquartered in Beit Haemek, near Haifa (Israel)

2019 revenue €20m to €25m with healthy growth profile; slightly dilutive EBITDA margin

Will be allocated to BPS and LPS Divisions; fully consolidated in Sartorius Stedim Biotech

Complementary to cell culture media business

Closing of transaction in Dec. 2019, total purchase price of approx. €45m for just over 50% of the shares

12 Overview | Strategy

Acquisition of Biological Industries in Q4 2019

Page 13: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

Acquisition includes bioanalytical tools for LPS; upstream and downstream technologies for BPS

2019 sales amounted to c. $170m; allocation of approx. $70m to LPS and approx. $100m to BPS; neutral impact on Group margin

~300 employees with production sites in the U.S., EMEA and China

Purchase price of $825m of which approx. 2/3 to be allocated to LPS and approx. 1/3 to BPS; financing secured

Announced in Q4 2019, deal closed after all regulatory approvals were received; consolidation in May 2020

13 Overview | Strategy

Acquisition of selected life science assets from Danaher

Page 14: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

Pie charts indicate completeness of product offering before the acquisitions

14

Acquisitions significantly strengthen positioning of both divisions

LPS: FortéBio highly synergetic with the bioanalyticsportfolio; expands spectrum to include protein analysis

iQue Screener (Sartorius)Identification of antibodies based on cell-based characteristics

Octet (FortéBio)Testing of the binding quality of antibodies to the target cell

IncuCyte | iQue Screener (Sartorius)Analysis of the cell behaviour

Portfolio complemented by businesses from Danaher and BI

Especially in chromatography and cellculture media

BPS: Acquisitions fit perfectly into the portfolio

Filtration

Fluid Management

Fermentation

Purification

Cell Culture Media

Overview | Strategy

Page 15: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

15

Sartorius 2025 targets and initiatives

2025 targetsStrategic initiatives

Regional Participate in strong Chinese market growth Continue to outperform the important U.S. market

Portfolio Add high-impact innovation, e.g. digital tools Enhance process development capabilities Expand into adjacent applications

Operations Accelerate workflows across the organization through digitalization

Extend manufacturing base in Asia

2025 targets are based on 2017 currency exchange rates; non-organic revenue growth is accounted for companies acquired from 2018 and onwards; EBITDA excluding extraordinary items; around two-thirds of the growth in the period 2020-2025 expected to be achieved organically and around one-third by acquisitions

~ 28%EBITDA margin

~ 1/3 Acquisitions

~ 2/3Organic

~€4bn Sales revenue

Overview | Strategy

Page 16: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

SSB | BPS Sartorius GroupLPS

~€2.8bnSales revenue

~30% EBITDA margin

~€1.2bnSales revenue

~25% EBITDA margin

~28%EBITDA margin

~€4bnSales revenue

2025 targets are based on 2017 currency exchange rates; EBITDA excluding extraordinary items

16 Overview | Strategy

Sartorius 2025 ambition per division

Page 17: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

Agenda

17

Overview | Strategy

Bioprocess Solutions Division

Lab Products & Services Division

FY 2020 Guidance | H1 2020 Results

Page 18: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

615.6

1,350.5

23.0

29.1

23252729313335

300500700900

110013001500

2014 2015 2016 2017 2018 2019

18

Track record of dynamic growth

High share of recurring revenuesGlobal footprint

Based on FY 2019 figures; sales CAGR in constant currencies; FY 2019 figures restated, CAGR unchanged 1 Excluding extraordinary items

Asia|Pacific~24%

Americas~37%

EMEA~39%

Single-use products

~75%

Equipment ~25%

Sales revenue, € in millions; EBITDA margin1 in %

Division sales by category

+15.7%CAGR

Division sales by region

Total solution provider for biomanufacturing

Bioprocess Solutions

Snapshot of the Bioprocess Solutions Division

Page 19: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

19

Production process design is inalterable for the lifetime of most drugs

Individually customized production process required for all drugs

Decisions for process design, and thus supplier selection, are typically made during clinical trials

Virus filtration

Viral clearance

Chroma-tography

Finalfilling

Cryo-preservation

Concen-tration

Sterile filtration

Culture mediapreparation

FermentationSeedcultivation

Scale-up

Clarification & centrifugation

UPSTREAM

DOWNSTREAM

Bioprocess Solutions

Covering most steps of the biopharma process chain

Page 20: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

20 Bioprocess Solutions

Leading positions in key technology platforms

Pie charts indicate completeness of product offering

Sartorius1 Merck | Millipore Pall Cytiva2

ThermoFisher

Top 3 Players

Filtration1. Merck | Millipore2. Danaher | Pall3. Sartorius

Fluid Management

1. Sartorius2. Thermo Fisher3. Merck | Millipore

Fermentation1. Sartorius2. Thermo Fisher3. Danaher | Cytiva

Purification1. Danaher | Cytiva2. Merck | Millipore3. Sartorius

Cell Culture Media

1. Thermo Fisher2. Merck | Millipore3. Danaher | Cytiva

1 Sartorius with strengthened portfolio after acquisition of selected life science assets from Danaher; 2 Formerly GE Biopharma

Danaher

Page 21: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

21

Biologics market growth forecastCAGR 2019 to 2023, € in billions

U.S.~155

China~62~€335bn

Europe~61

ROW~57

U.S.~110

China~35 ~€240bn

ROW~47

Europe~48

~+15% China

~+9% U.S.

~+6% Europe

Biologics market in China is at an early stage, but has strong growth potential

Supportive regulatory environment and solid industry foundation; biopharma considered a priority sector

Growth of fermentation capacity in China of 80% (2018 to 2022)

Bioprocess Solutions

U.S. remains most important market; China with highest growth rates

Page 22: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

22

0 03 1

7

22 2015

2012 2013 2014 2015 2016 2017 2018 2019

Growing number of biosimilar approvalsE.U. and U.S.

Biosimilars will outperform the biologics market€ in billions

~231 ~311

2019 2023

~9

~24

Biosimilars

Other biologics

~+30%CAGR

Major blockbuster biologics are going off-patent

Time-to-market is key as only the first providers are most likely profitable

Several approvals in Asia and Europe; U.S. at the beginning

For now, relatively small market but with strong growth

Single-use is the preferred platform for biosimilars

Bioprocess Solutions

Biosimilars: Strong growth, big opportunities

Page 23: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

23

Single-use market penetration expected to increase from ~35% to ~75%

Single-use products offer advantages over conventional stainless-steel devices

Capex|Opex reduction over entire lifecycle

Reduced risk of cross-contamination

Higher flexibility; advantageous for biosimilars

-25-35%

-55-65%-65-75%

Construction cost Energy cost Water cost

-30-50%

Time-to-market

Reference

Single-use

Bioprocess Solutions

Leader in the growing single-use technology market

Page 24: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

24

... not mature because

Underpenetrated global market

Strong flow of innovation

Time-consuming product development

... but maturing because

Increasing importance of product costs and time to market

Robustness and ease of use of tools are becoming more important

Companies invest in market consolidation

Data adopted from: Paul (2010) Nature Rev DD & Association of the British Pharmaceutical Industry (2017)

Cumulative investment and absolute survival rate in drug development

0

300

600

900

1200

1500

0

20

40

60

80

100

Targ

et to

lead

Pre

clin

ical

Pha

se 1

Pha

se 2

Pha

se 3

Reg

istr

atio

n

Cumulative investment

(€ in millions; rhs)

>10+ years

Absolute survival rate (in %; lhs)

Bioprocess Solutions

The biopharma market is not yet mature, but is maturing

Page 25: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

Sartorius offers the leading software for bioprocess data analytics

Enhanced process control and robustness

Improved product quality

Predictive process control

Powerful solutions for modeling and optimizing development and manufacturing

Help to gain insights from complex data sets

Data analytics just at the beginning in biomanufacturing and shows high potential

25

Monitoring and control

Dataaggregation

Data evaluation

Processoptimization

Bioprocess Solutions

Digitalization is arriving in biopharma

Page 26: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

26

More than half of 2019 BPS sales were generated with the Top 50 customers

No individual customer accounts for more than 5% of BPS sales revenue

No single drug accounts for more than 3% of BPS sales revenue

050

100150

200250300350

Sales to Top 50 customersin 2019, € in millions

Top 10 11 to 20 21 to 30 31 to 40 41 to 50

Cumulative share~25%

~40% ~45% ~50% ~55%

Limited dependence on individual accountsLong-term business relationships with leading global (bio-) pharma companies

Bioprocess Solutions

Limited dependence on individual accounts

Page 27: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

2

~+14% Organic CAGR1

27

1 CAGR 2013 to 2020e, excluding FX effects and acquisitions 2 Midpoint of 2020 guidance

2014 2015 2016 2017 2018 2019 2020

Pharmamarket

Biopharmamarket

Single-usepenetration

Market share gains

CAGR 4-7%

CAGR ~8%

Double-digit growth

Esp. in North America

Bioprocess Solutions

Four strong pillars drive above-average growth

Page 28: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

Agenda

28

Overview | Strategy

Bioprocess Solutions Division

Lab Products & Services Division

FY 2020 Guidance | H1 2020 Results

Page 29: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

325.3

476.5

16.0

21.6

13

15

17

19

21

23

25

27

29

100150

200250300350400450500550600

2016 2019

268.9305.5

17.416.0

14

16

18

20

22

24

26

28

30

100150

200250300350400450500550600

2012 2015

29

Global footprintDivision sales by region

Based on FY 2019 figures; sales growth and CAGR in constant currencies; FY 2019 figures restated, sales growth and CAGR unchanged 1 Excluding extraordinary items

Premium vendor for laboratories

Asia|Pacific~29%

Americas~27%

EMEA ~44%

Build-up of bioanalytics

portfolio since2016CAGR

+3.8%

CAGR +11.8%

Division in transition to a new growth and profitability profileSales revenue, € in millions; EBITDA margin1 in %

Lab Products & Services

Snapshot of the Lab Products & Services Division

Page 30: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

30

1 ½ years€60m

1 year€110m

5 ½ years€640m

4 ½ years€490m

Drug discovery Testing & improving

Clinical trials Drug approval

~€500m Average costs of drug

discovery

>10 yearsFrom drug discovery

to approval 1 in 10,000Chance for a candidateto make it to the market

Schematic example of biologic drug discovery with data from the Association of the British Pharmaceutical Industry

Our approach

Facilitate digitalization and automatization

Decrease likelihood of failure

Reduce time and costs in molecule development

Lab Products & Services

Our ambition: Reduce costly trial & error in drug discovery

Page 31: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

Automated imaging for live cell analysis

Analysis of cell health, morphology and movement by images and videos

Deep insights into biological processes

High-throughput screening and selection

Evaluation of cell health and functions

Fast screening and characterization of molecule candidates

Considerable acceleration of the

development of medications, e.g., in

cancer research

31 Lab Products & Services

Innovative bioanalytics for accelerated molecule development

Page 32: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

1 Becton Dickinson, Merck Millipore, PerkinElmer, Thermo Fisher 2 Beckman Coulter, Becton Dickinson, Merck Millipore, Thermo Fisher 3 Agilent Technologies, Danaher, Merck Millipore, PerkinElmer

IntelliCyt processes thousands of plates and generates large amounts of data for rapid and clear target identification

IncuCyte delivers video-based insights and improved workflows for real-time quantitative analysis of living cells

Platereaders3)

Microscopy High contentimaging1)

Flowcytometry2)

IntelliCyt

IncuCyte

Works on cells in suspension

Works on cells on 2D surface

Independent of cell attachment

Ric

hnes

sof

data

Sample throughput per plate

32 Lab Products & Services

Bioanalytics portfolio with little competition and high value added

Page 33: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

33 Lab Products & Services

FortéBio acquisition further strengthens positioning in bioanalytics

Innovative product portfolio with strong market position

Instruments, consumables and software for real-time, label-free measurement of biomolecular interactions

Octet as the key product uses unique, patented Bio-Layer-Interferometry (BLI) technology

Used to generate information on affinity, kinetics and concentration of proteins for selection, development & scale-up of biologics

Highly complementary to existing bioanalytics portfolio

OctetIdentify high-producing clones in expression library

ambr15Culture identifiedclones on small-scale

Octet | iQueScreenerAnalysis and characterization of cell line and antibodies

Application example: Cell line development

Page 34: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

34

~3.4~4.3

~1.2

~1.9

2019 2025

Addressable market of LPS€ in billions

LPS ex bioanalytics

Bioanalytics+3.5%CAGR

+8%CAGR

Different growth rate of bioanalyticsdue to high exposure to biopharmaceutical R&D

By 2025, two-thirds of the addressable market growth will come from bioanalytics

Thus, growth and profitability profile of LPS is changing over time

Lab Products & Services

Bioanalytics increases addressable market and changes growth profile

Page 35: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

35

Leading positions in laboratory products used for research and quality control

Average global market share of >10%

High gross margins offer potential for economies of scale

Growth potential especially in the U.S. and Asia

Lab balances Lab filtration

#2 #3

Pipettes

#4

Microb. analysis

#2

Lab Products & Services

Strong market position in key product categories

Page 36: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

36

Well established sample prep. portfolio

Premium instruments and consumables offering with strong global positions

Market share opportunities in certain regions to be addressed primarily by direct sales force

Unique bioanalytics portfolio established

Innovative technologies added through recent acquisitions

Combination with Sartorius’ global reach provides significant growth potential

Lab Products & Services

Scalable business with considerable growth and margin potential

Page 37: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

Agenda

37

Overview | Strategy

Bioprocess Solutions Division

Lab Products & Services Division

FY 2020 Guidance | H1 2020 Results

Page 38: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

38

1 Constant currencies 2 Underlying = excluding extraordinary items 3 Underlying EPS = based on net profit after non-controlling interest;adjusted for extraordinary items as well as amortization and based on a normalized financial result and tax rate

Sartorius Group in millions of € unless otherwise specified

H1 2019 H1 2020 in % in % cc1

Sales revenue 894.7 1,056.8 +18.1 +17.9

Order intake 974.3 1,244.8 +27.8 +27.5

Underlying EBITDA2 237.6 293.5 +23.5

Underlying EBITDA2 margin in % 26.6 27.8 +1.2pp

Underlying EPS3 (ord.) in € 1.48 1.81 +22.5

Underlying EPS3 (pref.) in € 1.49 1.82 +22.3

Acquisitions of Biological Industries and the Danaher portfolio contribute close to 4pp to sales growth, as expected

Underlying EBITDA driven by economies of scale; slightly negative impact from currencies

Dynamic top-line growth; further margin increase

FY 2020 Guidance | H1 2020 Results

Page 39: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

Americas€ in millions

39

EMEA€ in millions

Asia|Pacific€ in millions

Americas: Significant growth of BPS; LPS supported by acquisitions; impacted by lockdowns in Q2 EMEA: BPS strong; LPS demand driven by diagnostic test kits and lab consumables; weaker demand in other product areas Asia|Pacific: BPS with the highest momentum; LPS demand stabilized after lockdown lifted in China

Acc. to customers‘ location; growth in constant currencies

Sales by Regionin %

224.5 264.2

H1 2019 H1 2020

308.2373.1

H1 2019 H1 2020Asia|Pacific

~ 25%

Americas~ 35%

EMEA ~ 40%

362.0419.5

H1 2019 H1 2020

+19.7 % +18.4%+16.0 %

€1056.8m

Double-digit growth in all geographies

FY 2020 Guidance | H1 2020 Results

Page 40: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

Order Intake€ in millions

40

Sales Revenue€ in millions

Underlying EBITDA & Margin € in millions

191.5247.2

H1 2019 H1 2020

735.6984.9

H1 2019 H1 2020

665.8809.3

H1 2019 H1 2020

28.8%30.5%

Order intake positively impacted by demand for Covid-19 medicines; strong project business, especially in Asia|Pacific Non-organic growth from Biological Industries and Danaher portfolio a good 2pp, as expected Underlying EBITDA margin rises due to economies of scale, despite slight dilution of acquisitions and FX

+33.5% cc+33.9% +29.1%

+21.3% cc +21.6%

BPS: Strong performance across all product categories and regions

1 1 1

1 H1 2019 figures reported: Order intake €746.4m, sales €676.6m, underlying EBITDA €198.3m

FY 2020 Guidance | H1 2020 Results

Page 41: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

Order Intake€ in millions

41

Sales Revenue€ in millions

Underlying EBITDA & Margin € in millions

46.2 46.4

H1 2019 H1 2020

238.8 259.9

H1 2019 H1 2020

228.9 247.5

H1 2019 H1 2020

20.2% 18.7%

Difficult economic environment due to pandemic, with dampening effect on demand Acquisitions contribute close to 9pp to sales growth as expected Underl. EBITDA margin impacted by lower capacity utilization at the beginning of the year and by approx. -0.5pp FX effect

+8.9% cc +8.9%

+8.1% cc +8.1%

+0.4%

LPS: Robust sales development

1 1 1

1 H1 2019 figures reported: Order intake €228.0m, sales €218.1m, underlying EBITDA €39.4m

FY 2020 Guidance | H1 2020 Results

Page 42: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

42

1 Underlying net profit = net profit adjusted for extraordinary items, amortization and based on a normalized financial result and tax rate 2 After non-controlling interest3 Net cash flow from investing activities and acquisitions

Sartorius Group in millions of € unless otherwise specified

H1 2019 H1 2020 in %

Underlying EBITDA 237.6 293.5 +23.5

Extraordinary items -10.6 -26.1 n.m.

Financial result -9.9 -20.3 n.m.

Underlying net profit1,2 101.5 124.3 +22.4

Reported net profit2 82.3 81.1 -1.5

Operating cash flow 165.1 215.4 +30.4

Investing cash flow3 -116.0 -849.5 n.m.

CAPEX ratio (in %) 12.8 8.5 -4.3pp

Net operating cash flow mostly driven by higher earnings and factoring program (~€89m)

Extraordinary items influenced by M&A

Investing cash flow impacted by closing of acquisition of Danaher portfolio

Tax rate at 30% (+3pp vs. PY) due to accounting of tax risks; not cash-effective in H1

Operating cash flow increases significantly

FY 2020 Guidance | H1 2020 Results

Page 43: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

43

Key Financial Indicators

Sartorius GroupDec. 31,

2019June 30,

2020

Equity ratio in % 38.1 30.1

Net debt in millions of € 1,014.0 1,669.6

Net debt | underlyingEBITDA 2.0 2.8 Q1-Q4

2014Q1-Q42015

Q1-Q42016

Q1-Q42017

Q1-Q42018

Q1-Q42019

0.0

1.0

2.0

3.0

4.0

0

500

1,000

1,500

2,000

Net debt in millions of € (lhs) Net debt to underlying EBITDA (rhs)

Net Debt and Net Debt to Underlying EBITDA

Financial indicators remain robust

Q1-Q22020

Balance sheet influenced by the recent acquisitions

FY 2020 Guidance | H1 2020 Results

Page 44: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

44

Outlook for 2020 increased for BPS and the Group; uncertainty remains

FY 2020 Guidance1 [change vs. previous guidance]Sales revenue

growthUnderlying

EBITDA margin

Sartorius Group ~ 22% - 26% [+7pp] ~ 28.5% [+1pp]- thereof Biological Industries 1.5pp slightly dilutive

- thereof Danaher portfolio 5pp neutral

Bioprocess Solutions ~ 26% - 30% [+9pp] ~ 31.0% [+1pp]- thereof Biological Industries 1pp slightly dilutive

- thereof Danaher portfolio 3.5pp -0.5pp

Lab Products & Services ~ 10% - 14% ~ 20.0%- thereof Biological Industries 2.5pp slightly dilutive

- thereof Danaher portfolio 10pp 1.5pp

CAPEX ratio ~10% (FY 2019: 12.3%); net debt to underlying EBITDA slightly below 2.75 (previously around 2.75; FY 2019: 2.0)

FY 2020 tax rate expected at 30% (+2.2 pp vs. PY) due to accounting of tax risks

Guidance based on the assumption that supply chains are stable and production lines remain in operation

Mid-term guidance up to 2025 unchanged

1 In constant currencies

FY 2020 Guidance | H1 2020 Results

Page 45: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

Appendix

45

Page 46: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

46

High entry barriers, low price-sensitivity and consolidated

competitive landscape

Biopharma market fueled by long-term growth

drivers

Leading market positions in key technologies and high brand awareness

Global presence with strong base in growth

regions

Diversified revenue base and high share of recurring

revenues provide low volatility

Proven growth track record: Sales CAGR of ~14% over

the last five years

12 3

Appendix

Sartorius shares – an attractive investment

Page 47: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

Sartorius Stedim Biotech S.A. Stock market listed in France

47

1 Information on shareholdings and shares in free float pursuant to the disclosure requirements of Sections 33 et seq. of the German Securities Trading Act (WpHG) and the shareholders’ own disclosures. These reporting obligations and own disclosures refer only to voting shares and not to non-voting preference shares.

100%~74%

Other Sartorius Subsidiaries

Lab Products & Services DivisionBioprocess Solutions Division

Sartorius Group Operational Setup

Sartorius AGStock market listed in Germany1

>50% Administered by executor~34% Bio-Rad Laboratories

~9% Treasury shares~5% Family owned~2% Free floatO

rdin

ary

shar

es~74% Sartorius AG~26% Free float

Sartorius Group Legal Setup

~91% Free float~9% Treasury shares

Pref

eren

ce sh

ares

Appendix

Sartorius legal & operational structure

Page 48: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

48

1 Excluding treasury shares held by Sartorius AG 2 As of July 21, 2020

Share key factsISIN DE0007165631 (preference share) |

DE0007165607 (ordinary share)

Ticker SRT3 (preference share) | SRT (ordinary share)

Number of 68,388,292 - thereof preference shares: 34,176,068 shares1 ordinary shares: 34,212,224

Indices DAX 50 ESG | MDAX | TecDAX | MSCI Germany Index | CDAX | Prime All Share Index | Technology All Share Index | STOXX Europe 600

Market cap.2 €21.3bn

Appendix

Share price performance

0%

100%

200%

300%

400%

500%

600%

Jan-

16

Mar

-16

May

-16

Jul-1

6

Sep-

16

Nov

-16

Jan-

17

Mar

-17

May

-17

Jul-1

7

Sep-

17

Nov

-17

Jan-

18

Mar

-18

May

-18

Jul-1

8

Sep-

18

Nov

-18

Jan-

19

Mar

-19

May

-19

Jul-1

9

Sep-

19

Nov

-19

Jan-

20

Mar

-20

May

-20

Jul-2

0

Sartorius (prefs.)

Sartorius (ord.)

Sartorius Stedim Biotech

DAX

MDAX

NASDAQ Biotech

Page 49: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

49

Fluid management

PurificationFiltration

Fermentation

Appendix

A sampling of the Bioprocess Solutions’ product portfolio

Page 50: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

50

Pipettes

BioanalyticsLab balances | Lab water systems

Lab filtration | Microb. analysis

Appendix

A sampling of the Lab Products and Services’ product portfolio

Page 51: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

51

Recap 2020 targets and initiatives

2020 targetsStrategic initiatives

Appendix

~ 26-27% EBITDA margin

~ 1/4 Acquisitions

~ 3/4Organic

~€2bnSales revenue

Regional Gain share in North America Leverage strong market growth in Asia

Portfolio Complementary extensions through

alliances and acquisitions Own product development

Operations Expansion of production capacity Significant investments into IT infrastructure

2020 targets are based on 2015 currency exchange rates; EBITDA excluding extraordinary items; around three-quarters of the growth expected to be achieved organically and around one-quater by acquisitions

Page 52: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

52

Rainer Lehmann, CFO

Joined Sartorius in 2005Member of the Board since 2017

Finance, Information Technology, Business Processes

Joachim Kreuzburg, CEO

Joined Sartorius in 1999Member of the Board since 2003

Group Strategy, Corporate Research, Human Resources, Legal & Compliance, Communications

René Fáber

Joined Sartorius in 2002Member of the Board since 2019

Bioprocess Solutions Division

Gerry Mackay

Joined Sartorius in 2015Member of the Board since 2019

Lab Products & Services Division

Appendix

Executive Board of Sartorius AG

Page 53: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

53

Petra Kirchhoff

Head of Corporate Communications & IR

Phone: +49.551.308.1686E-mail: [email protected]

Sartorius Corporate Administration GmbHOtto-Brenner-Straße 2037079 Göttingen, Germany

October 20, 2020Publication Nine-Month Results 2020 | Göttingen

Ben Orzelek

Head of Investor Relations

Phone: +49.551.308.1668E-mail: [email protected]

Appendix

Financial calendar and contacts

Page 54: Titelfolie mit langer Überschrift, zwei- oder mehrzeilig, TT Norms … · Biologics market in China is at an early stage, but has strong growth potential Supportive regulatory environment

Visit our IR website